Public consultation on applications to be considered by the MSAC (Nov 2022)

Closed 7 Oct 2022

Opened 22 Jun 2022


Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on
24-25 November 2022.

MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.   

Consultation input must be received by no later than Friday, 7 October 2022 for it to be considered by MSAC.

To provide input on any of the applications listed, please click on the relevant application link below. This will take you to the specific MSAC application webpage which includes further information about the medical service/ technology. 

You can then download and complete a consultation survey or provide a separate file with your input to

Further information on MSAC’s consultation process is also available on the MSAC website.

Applications scheduled to be considered:


1662.1 - The reduction of mitral regurgitation through tissue approximation using transvenous/transeptal techniques

New applications:

1627 - Point-of-care testing for sexually transmitted infections provided by Aboriginal Medical Services or Aboriginal Community Controlled Heath Services in rural or remote areas

1629 - Defensive Antibacterial Coating (DAC) 5ml Kit

1647 - Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma

1669 - KRAS G12C variant testing to determine eligibility for PBS-subsidised sotorasib second-line therapy in patients with locally advanced or metastatic non small cell lung cancer

1675 - Whole Genome Sequencing for the diagnosis of mitochondrial disease

1680 - Genetic testing for childhood hearing impairment

1684 - Genetic testing for variants associated with haematological malignancies

1685 - Ventral rectopexy for the treatment of rectal prolapse and intussusception

1691 - PromarkerD testing in patients with type 2 diabetes to determine the risk of developing diabetic kidney disease

1707 - Measuring minimal residual disease in acute lymphoblastic leukaemia using next generation sequencing assays to guide treatment decision

1711 - Review of MBS items for subacromial decompression

1718 - PD-L1 (Programmed Death-Ligand 1) immunohistochemistry testing for persistent, recurrent, or metastatic cervical cancer, to determine eligibility for pembrolizumab treatment

1721 - Small gene panel testing for non-small cell lung carcinoma

1723 - Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia

What happens next

Once the consultation closes, submissions will be compiled and considered by MSAC.

Once it has finalised its appraisal of an application for public funding, MSAC publishes a Public Summary Document (PSD). The PSD captures MSAC deliberations and key advice to the Minister, which is generally to either support funding; not support funding; or defer consideration. 

PSDs are generally published approximately three (3) months after the MSAC meeting at which the application was considered. The PSD can be located on the relevant application webpage on the MSAC website.


  • Anyone from any background


  • All